Positron emission tomography with macrophage targeting to select individuals at risk for rheumatoid arthritis.

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-513538-40-02

Enrollment

Registered

2024-12-09

Start date

Unknown

Completion date

Unknown

Last updated

2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ACPA positive arthralgia

Brief summary

Sensitivity, Specificity, Positive predictive value, Negative predictive value

Detailed description

Relationship of PET positivity and time to development of clinical arthritis., Cut-off value(s) for this/these specific outcome measure(s) in relation todevelopment of RA within one year.

Interventions

DRUG[18F]Fluor-PEG-Folate

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Sensitivity, Specificity, Positive predictive value, Negative predictive value	—

Secondary

Measure	Time frame
Relationship of PET positivity and time to development of clinical arthritis., Cut-off value(s) for this/these specific outcome measure(s) in relation todevelopment of RA within one year.	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026